BD Expands Testing Capabilities to Help Clinicians Improve Diagnostic Accuracy and Efficiency

Rhea-AI Summary

BD (NYSE: BDX) announced the BD Vacutainer® Urine Complete Cup Kit on February 23, 2026, a three-tube urine collection system designed to preserve specimen integrity, reduce repeat collections, and streamline testing workflows.

The kit includes culture, urinalysis, and discard tubes, a sterile cup with integrated transfer device, and a Castile wipe. Available in the United States with Hemogard and conventional stoppers and compatible with automated workflows; orders available through local sales representatives.

Key Figures

Contaminated urine cultures: 44 percent Collection system tubes: three-tube

2 metrics

Contaminated urine cultures 44 percent Patients in a study receiving inappropriate antibiotic therapy

Collection system tubes three-tube Design of BD Vacutainer Urine Complete Cup Kit

Market Reality Check

Price: $185.46 Vol: Volume 2,434,191 vs 20-da...

normal vol

$185.46 Last Close

Volume Volume 2,434,191 vs 20-day average 3,046,204 (relative volume 0.8x) ahead of this product launch. normal

Technical Shares at $185.46, trading slightly below 200-day MA of $186.70 and about 21.19% below the 52-week high.

Peers on Argus

BDX was up 1.6% while peers were mixed: ALC (-0.51%), RMD (+1.35%), WST (-0.05%)...

BDX was up 1.6% while peers were mixed: ALC (-0.51%), RMD (+1.35%), WST (-0.05%), BAX (+0.37%), HOLX (+0.39%). No coordinated sector move or momentum flags appeared.

Historical Context

5 past events · Latest: Feb 19 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 19	Management change	Neutral	-0.1%	Appointment of new executive vice president and general counsel.
Feb 10	Debt tender offers	Positive	-17.2%	Launch of tender offers to repurchase up to $1.6B of senior notes.
Feb 09	Business spin-off	Positive	-1.3%	Completion of Biosciences & Diagnostic Solutions spin-off and cash receipt.
Feb 09	Combination completion	Positive	-1.3%	Waters completes combination with BD’s divested businesses via Reverse Morris Trust.
Feb 09	Earnings release	Neutral	-1.3%	Q1 FY2026 results and reaffirmed guidance for New BD revenue and EPS.

Pattern Detected

Recent strategic and capital structure announcements with generally positive implications were followed by negative price reactions, suggesting a pattern where the stock underperformed on ostensibly constructive news.

Recent Company History

Over the past few weeks, BD reported Q1 FY2026 results, completed the spin-off and combination of its Biosciences & Diagnostic Solutions business with Waters, and announced large tender offers for up to $1.6 billion of debt. These events reshaped the portfolio and capital structure but saw share price declines of up to 17.22% the next day. The current product launch for the BD Vacutainer Urine Complete Cup Kit fits within an ongoing operational and portfolio transition theme.

Market Pulse Summary

This announcement introduces the BD Vacutainer Urine Complete Cup Kit, a three-tube system aimed at ...

Analysis

This announcement introduces the BD Vacutainer Urine Complete Cup Kit, a three-tube system aimed at preserving specimen quality, expanding testing from a single urine sample, and reducing contamination. The cited study, where 44 percent of patients with contaminated cultures received inappropriate antibiotics, highlights clinical risk the kit targets. In light of BD’s recent portfolio reshaping and debt tenders, investors may watch adoption rates, integration into automated workflows, and any follow-on product extensions in specimen management.

Key Terms

urinalysis

1 terms

urinalysis medical

"a tube to support urinalysis testing for general wellness and signs of disease"

A urinalysis is a laboratory examination of a urine sample that checks for signs of disease, infection, kidney function, or the presence of drugs and chemicals. For investors, urinalysis matters because its results can affect clinical trial safety assessments, regulatory approvals, or routine employee health monitoring—similar to a car’s dashboard lights that reveal hidden problems before they become major failures.

AI-generated analysis. Not financial advice.

The BD Vacutainer® Urine Complete Cup Kit preserves specimen quality, streamlines testing, and helps reduce repeat collections to support better patient care

FRANKLIN LAKES, N.J., Feb. 23, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the launch of the BD Vacutainer® Urine Complete Cup Kit, a three-tube collection system that expands and supports broader testing capabilities from a single urine specimen.

The new kit is designed to preserve sample integrity and improve workflow efficiency, while reducing exposure risks for healthcare workers and minimizing the need for repeat patient collections. With an innovative third tube design, clinicians can perform greater testing without manually transferring urine or collecting a new sample, helping reduce contamination risks and supporting safer, more efficient patient care.

"Improving diagnostic accuracy starts long before a sample reaches the lab," said Bridget Bagnato, worldwide president of Specimen Management at BD. "This kit reflects the innovation we deliver to help clinicians determine effective treatment options through more accurate diagnosis and ultimately support better patient management."

Urine testing is a critical, non‑invasive tool for diagnosing conditions such as pregnancy, urinary tract infections, metabolic disorders, and cancer, as well as for assessing kidney function. Contaminated or improperly collected specimens can lead to the wrong result, inappropriate treatment or delayed care. One recent study found that nearly 44 percent of patients with contaminated urine cultures received inappropriate antibiotic therapy, underscoring the clinical impact of preanalytical errors[i]. Closed-system solutions, including products in the BD Vacutainer® Urine Collection portfolio, help minimize contamination risk and improve overall efficiency across the urine specimen management continuum for accurate, timely results.

The BD Vacutainer® Urine Complete Cup Kit features:

• a sterile urine cup and lid with integrated transfer device
• a tube to support culture and sensitivity testing for detecting and identifying bacteria or fungi causing infection
• a tube to support urinalysis testing for general wellness and signs of disease
• a discard tube that contains no additive
• a castile wipe for patient prep prior to providing the sample

Available in the United States with both Hemogard™ and conventional stoppered tubes, the kit is compatible with a broad range of diagnostic equipment and can support automated workflows.

BD Vacutainer® Urine Complete Cup Kits are now available for order through local sales representatives. More information is available at bd.com

About BD
BD is one of the world's largest pure-play medical technology companies with a Purpose of advancing the world of health™ by driving innovation across medical essentials, connected care, biopharma systems and interventional. The company supports those on the frontlines of healthcare by developing transformative technologies, services and solutions that optimize clinical operations and improve care for patients. Operating across the globe, with more than 60,000 employees, BD delivers billions of products annually that have a positive impact on global healthcare. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase clinical efficiency, improve safety and expand access to healthcare. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X @BDandCo or Instagram @becton_dickinson.

Contacts:
Media	Investors
Matt Marcus VP, Public Relations Matt.Marcus@bd.com	Shawn Bevec SVP, Investor Relations Investor_Relations@bd.com

ⁱ Klausing BT, Tillman SD, Wright PW, Talbot TR. The influence of contaminated urine cultures in inpatient and emergency department settings. Am J Infect Control. 2016;44(10):1166-1167. doi:10.1016/j.ajic.2016.03.055.

View original content to download multimedia:https://www.prnewswire.com/news-releases/bd-expands-testing-capabilities-to-help-clinicians-improve-diagnostic-accuracy-and-efficiency-302694057.html

SOURCE BD (Becton, Dickinson and Company)

FAQ

What is the BD Vacutainer Urine Complete Cup Kit announced by BDX on Feb 23, 2026?

It is a three-tube urine collection kit designed to preserve samples and reduce repeat collections. According to the company, the kit includes culture, urinalysis, and discard tubes plus an integrated transfer device and patient prep wipe for safer collection.

How does the BDX urine kit improve diagnostic accuracy for clinicians?

It reduces contamination and repeat sampling by enabling multiple tests from one specimen. According to the company, the closed-system third tube and integrated transfer device limit manual transfers and lower contamination risk during preanalytical handling.

When and where is the BD Vacutainer Urine Complete Cup Kit available for order (BDX)?

The kit is available in the United States as of February 23, 2026 for ordering through local sales representatives. According to the company, it ships with Hemogard and conventional stoppered tube options and supports automated workflows.

What tests can clinicians run from a single specimen using the BDX urine kit?

Clinicians can perform culture and sensitivity plus urinalysis from one urine specimen without manual transfer. According to the company, the kit’s third-tube design enables broader testing while preserving sample integrity.

Is the BD Vacutainer Urine Complete Cup Kit compatible with lab automation (BDX)?

Yes — the kit is compatible with a broad range of diagnostic equipment and can support automated workflows. According to the company, it is offered with Hemogard and conventional stoppers to suit lab systems.

How does the BD kit address contamination risk and healthcare worker exposure?

The closed-system design and integrated transfer device aim to minimize contamination and exposure during specimen handling. According to the company, this reduces repeat collections and supports safer, more efficient patient care.